CoChat

Efficacy and Safety of Quetiapine-XR as Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression With Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-Controlled Trial

Gao, Keming, Wu, Renrong, Kemp, David E., Chen, Jun, Karberg, Elizabeth, Conroy, Carla, Chan, Philip, Ren, Ming, Serrano, Mary Beth, Ganocy, Stephen J., Calabrese, Joseph R. · 2014 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record.

Abstract

OBJECTIVE: To study the efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar I or II depression with comorbid generalized anxiety disorder (GAD) and other comorbidities. METHOD: The study was conducted from January 2007 to November 2011. The Mini-International Neuropsychiatric Interview was used to ascertain the diagnosis of DSM-IV bipolar disorder, GAD, and other Axis I disorders. Eligible patients were randomly assigned to quetiapine-XR or placebo for up to 8 weeks. The Hamilton Depression Rating Scale-17 items (HDRS-17) was used as a primary outcome to evaluate the difference between the 2 groups using the change from baseline to end of study. Last observation carried forward and mixed-effects modeling for repeated measures were used to analyze the primary and secondary outcome measures. RESULTS: Of the 120 patients screened, 100 patients were randomized to receive quetiapine-XR (n = 50) or placebo (n = 50). Twenty-six patients in the quetiapine-XR and 18 in the placebo group completed the study. The mean quetiapine-XR dose was 276 ± 50 mg/d (50-300 mg/d). There was no significant difference between the 2 groups in the change from baseline to end of study in HDRS-17 total score with an effect size of 0.19 favoring quetiapine-XR. There were also no significant differences between the 2 groups in secondary efficacy and safety outcome measures. CONCLUSIONS: Quetiapine-XR was not significantly superior to placebo in bipolar I or II depression with GAD and other comorbidities, suggesting that data from relatively "pure" bipolar patients may not be generalizable to a highly comorbid population. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00671853.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.13m08847

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 35

Metadata

Authors
Gao, K., Wu, R., Kemp, D. E., Chen, J., Karberg, E., Conroy, C., Chan, P., Ren, M., Serrano, M. B., Ganocy, S. J., & Calabrese, J. R.
Affiliations
  • University Hospitals Cleveland Medical Center (US)
  • Central South University (CN)
  • Shanghai Jiao Tong University (CN)
  • Case Western Reserve University (US)
Venue
The Journal of Clinical Psychiatry
Published
2014-06-24
Volume
75
Issue
10
Pages
1062-1068
ISSN
0160-6689 (ISSN-L)
OpenAlex
W1980958940
Cited by
29
References
0
Citations by year
2025: 2 · 2024: 1 · 2023: 1 · 2021: 3 · 2019: 1 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 7
FWCI
4.32
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
bipolar depression, generalized anxiety disorder, comorbidities, adjunctive therapy, mood stabilizers, monotherapy, atypical antipsychotics, treatment efficacy, drug safety
MeSH terms
Quetiapine Fumarate, Acute Disease, Adult, Anxiety Disorders, Bipolar Disorder, Delayed-Action Preparations, Dibenzothiazepines, Double-Blind Method, Drug Synergism, Female, Humans, Male, Middle Aged, Placebos, Antipsychotic Agents, Comorbidity, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Quetiapine-XR as Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression With Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.4088/jcp.13m08847
The paper
Gao, K., Wu, R., Kemp, D. E., Chen, J., Karberg, E., Conroy, C., Chan, P., Ren, M., Serrano, M. B., Ganocy, S. J., & Calabrese, J. R. (2014). Efficacy and Safety of Quetiapine-XR as Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression With Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-Controlled Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13m08847

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.